Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

10.90 +0.99 (+9.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Stoke Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 56 companies set new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
What 8 Analyst Ratings Have To Say About Stoke Therapeutics
Via Benzinga
Why Ryanair Holdings Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Tupperware Brands Corporation (NYSE: TUP) shares jumped 59% to $1.43 on above-average volume amid retail investor interest. 
Via Benzinga
Scholastic, Matson, Digital World Acquisition And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 90 points on Friday. Here are some big stocks recording gains in today’s session. Digital World Acquisition Corp. (NASDAQ: DWAC) climbed 69%... 
Via Benzinga
Analyst Expectations for Stoke Therapeutics's Future
Via Benzinga
Analyst Ratings for Stoke Therapeutics
Via Benzinga
12 Analysts Have This to Say About Stoke Therapeutics
Via Benzinga
Where Stoke Therapeutics Stands With Analysts
Via Benzinga
Stoke Therapeutics to Host Webinar to Present New Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics: Q1 Earnings Insights
Via Benzinga
What 7 Analyst Ratings Have To Say About Stoke Therapeutics
Via Benzinga
Adobe And 2 Other Stocks Insiders Are Selling
The S&P 500 closed lower on Wednesday after the Fed increased rates by 25 basis points, as widely expected. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present at the BofA Securities Health Care Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
Via Benzinga
Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Credit Suisse Maintains Outperform Rating for Stoke Therapeutics: Here's What You Need To Know
Via Benzinga
6 Analysts Have This to Say About Stoke Therapeutics
Via Benzinga
Expert Ratings for Stoke Therapeutics
Via Benzinga
Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Participate at Upcoming March Investor Conferences
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.